Photo of Michael Jann

View Scopus Profile

Michael Jann, PharmD

  • 4813 Citations
  • 38 h-Index
1980 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Area of Expertise

Dr. Jann’s research interests are in pharmacogenomics, pharmacokinetics, and pharmacodynamics of CNS and other molecules in clinical research.

Education/Academic qualification

BS in Biology, California State University Los Angeles

PharmD, University of Southern California

Fingerprint Dive into the research topics where Michael Jann is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 2 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Do asians patients require only half of the clozapine dose prescribed for Caucasians? A critical review

Jann, M., 1 Jan 2020, In : Indian Journal of Psychological Medicine. 42, 1, p. 1-3 3 p.

Research output: Contribution to journal › Editorial

1 Scopus citations

An elective course in lesbian, gay, bisexual, and transgender health and practice issues

Jann, M. W., Penzak, S. R., White, A. & Tatachar, A., 1 Jan 2019, In : American journal of pharmaceutical education. 83, 8, p. 1723-1731 9 p., 6967.

Research output: Contribution to journal › Article

    • 1 Scopus citations

    Selective serotonin reuptake inhibitor use and risk of gastrointestinal and intracranial bleeding

    Yuet, W. C., Derasari, D., Sivoravong, J., Mason, D. & Jann, M., Feb 2019, In : Journal of the American Osteopathic Association. 119, 2, p. 102-111 10 p.

    Research output: Contribution to journal › Review article

    • 5 Scopus citations

    The Evolving Role of Pharmacists in Transgender Health Care

    Redfern, J. S. & Jann, M. W., 11 Apr 2019, In : Transgender Health. 4, 1, p. 118-130 13 p.

    Research output: Contribution to journal › Review article

    Open Access
    • 2 Scopus citations

    Correction to: Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents (CNS Drugs, (2018), 32, 3, (241-257), 10.1007/s40263-018-0508-6)

    Jann, M. W. & Penzak, S. R., 1 Jun 2018, In : CNS Drugs. 32, 6, 1 p.

    Research output: Contribution to journal › Comment/debate